Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Active Ankylosing Spondylitis Clear all
Completed Phase 3 Interventional Results available

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

NCT01358175
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Boise, Idaho • Cedar Rapids, Iowa • Portland, Oregon + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

NCT02159053
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Anniston, Alabama • Upland, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

NCT02696785
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

NCT01649375
View directory record Official record
Conditions
Anklyosing Spondylitis
Interventions
Secukinumab (75 mg), Placebo, Secukinumab (150 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of SUNPG1622

NCT02980705
View directory record Official record
Conditions
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Interventions
SUNPG1622 I dose, Placebo dose
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

NCT01583374
View directory record Official record
Conditions
Ankylosing Spondyloarthritis
Interventions
Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
20
States / cities
Peoria, Arizona • La Jolla, California • Palm Desert, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional Results available

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT04947579
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
CC-99677, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640
View directory record Official record
Conditions
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chronic Pain, Couples, & Physical Activity

NCT04077164
View directory record Official record
Conditions
Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions
No intervention, observational only.
Other
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 22, 2026, 1:07 PM EDT
Withdrawn Phase 3 Interventional

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT03928743
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

NCT00085644
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
adalimumab (D2E7), placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471
View directory record Official record
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

NCT03178487
View directory record Official record
Conditions
Ankylosing Spondylitis (AS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Microbiome and Axial Spondyloarthritis

NCT04713995
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Dietary recommendations
Other
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

NCT00811499
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

NCT03502616
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 22, 2026, 1:07 PM EDT